Latest News

Saakshi Khattri, MD, discusses mental health screening gaps in psoriasis and a new Th17/type 2 immune signature study pointing toward personalized care.

Saakshi Khattri, MD, discusses oral TYK2 inhibitor and IL-23 antagonist data alongside weight-loss combination therapy reshaping psoriasis and PsA care.

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd

Abbott's Libre Duo 10 Day earned FDA De Novo authorization, becoming the first continuous dual glucose-ketone monitor for diabetes.

Nipocalimab-aahu (IMAAVY) is now approved for wAIHA, based on Phase 2/3 ENERGY trial data showing durable hemoglobin response.

In this segment of his Q&A interview, Charles Lynde, MD, reviews upadacitinib's safety profile in the UP-AA trials and how it could reshape alopecia areata care.

In this Q&A, Charles Lynde, MD, highlighted upadacitinib's impact on severe alopecia areata in new phase 3 data addressing the hair loss condition.

This episode discusses the recent results from trials of IcoSema and a new highly concentrated insulin aspart.

United Therapeutics' ralinepag NDA rests on phase 3 ADVANCE OUTCOMES data showing a 55% reduction in clinical worsening versus placebo.

A new study from the AHA has indicated the real prevalence of CKM syndrome stages 0-3 in young adults in their 20s.

Stay updated with the latest healthcare breakthroughs, including a new lerodalcibep FDA approval and phase 3 avexitide data in post-bariatric hypoglycemia.

A recent study has shown that a significantly greater proportion of patients with HF were correctly identified when testing NT-proBNP levels.

Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.

This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.

PAH specialists discuss upfront combination therapy and the disconnect between guidelines and community practice.

This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.

Deupirfenidone 825 mg reduced 26-week FVC decline by 91.0 mL versus placebo in the phase 2b ELEVATE-IPF trial in idiopathic pulmonary fibrosis.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

The generic nasal spray is bioequivalent to Haleon's Flonase, indicated for nasal symptoms of allergic rhinitis.

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

The Fast Track designation adds to LTI-03's prior Orphan Drug status as Rein Therapeutics advances the Phase 2 RENEW trial in IPF.

The FDA granted accelerated approval to the first gene therapy for GSD1a, based on a 31% reduction in daily cornstarch intake versus placebo.

Academic pulmonologists from Mass General, Duke, and Cleveland Clinic discuss biologic selection, mucus plugging, and more.